Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China (Q28553675)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
scientific article

    Statements

    Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China (English)
    0 references
    Shuyan Gu
    0 references
    Yuhang Zeng
    0 references
    Demin Yu
    0 references
    Xiaoqian Hu
    0 references
    Hengjin Dong
    0 references
    22 November 2016
    11
    0 references
    e0167190
    0 references
    11
    0 references

    Identifiers

    0 references
    0 references
     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit